Data from St. Jude Medical’s ASSERT Implantable Device Monitoring Study Published in New England Journal of Medicine

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical (NYSE:STJ), a global medical device company, today announced the publication of results from the ASSERT cohort study in the New England Journal of Medicine (NEJM). The ASSERT study, or ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial, was designed to determine whether the detection of arrhythmias using pacemaker-based diagnostics predicts an increased risk of stroke in elderly, hypertensive patients without any history of atrial fibrillation (AF).

“St. Jude Medical is committed to providing our customers with clinically relevant information that allows them to deliver more timely and effective care to patients around the world.”

The study results, previously presented at an American Heart Association Scientific Sessions meeting, found that pacemaker patients who have no history of atrial tachycardia (AT) or AF, but do have device-detected arrhythmias, are approximately 2.5 times more likely to have a stroke than patients who do not have device-detected arrhythmias. The trial was sponsored by St. Jude Medical and was conducted by the Population Health Research Institute of McMaster University and Hamilton Health Sciences in Hamilton, Canada.

“Approximately 85 percent of atrial arrhythmias documented in the study were picked up only by the pacemaker, proving the device plays a very significant role in identifying patients with a higher risk of stroke,” said Dr. Jeff S. Healey, principal investigator for the arrhythmias program at the Population Health Research Institute. “This monitoring technology is a built-in diagnostic tool and a huge value-add to further assist physicians in properly treating their patients.”

The study included 2,580 pacemaker and ICD patients over the age of 65 with hypertension and no history of AF. Subclinical (non-symptomatic) atrial tachyarrhythmias detected by implanted devices occurred in over 10 percent of patients at three months. The risk of systemic embolism (or stroke) associated with non-symptomatic atrial tachyarrhythmias was 13 percent. The diagnostic data and alerts available through St. Jude Medical implantable devices allow physicians and patients to be notified whenever a patient experiences significant atrial arrhythmias (abnormal heartbeats) in the heart's upper chambers, such as AT or AF.

“The publication of these findings reminds us how important it is to identify patients with an increased risk of stroke. Diagnostic tools and remote monitoring capabilities already found in St. Jude Medical pacemakers and ICDs make it easier for physicians to capture information to manage AT and AF even when the arrhythmias are not accompanied by symptoms,” said Dr. Mark Carlson, chief medical officer and senior vice president of research and clinical affairs for the St. Jude Medical Cardiac Rhythm Management Division. “St. Jude Medical is committed to providing our customers with clinically relevant information that allows them to deliver more timely and effective care to patients around the world.”

About Atrial Fibrillation

Atrial fibrillation (AF) is a chaotic, uncontrolled heart rhythm. It occurs when the upper chambers of the heart (atria) contract rapidly and irregularly - from 350 to 600 times per minute compared to a normal heart rhythm of 60 to 100 times per minute. AF is known to be a common risk factor for, and cause of, stroke. Because the atria contract so rapidly and irregularly during AF, the heart cannot beat effectively and blood is not pumped completely out of the atria. Blood that pools in the atria may clot and, if the clot moves to an artery in the brain, stroke may occur. Studies show that AF increases the risk of stroke five-fold. The risk for stroke related to AF increases with age, and AF potentially leads to a range of other debilitating symptoms as well.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended October 1, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.